Traders News Source released a report with no obligation on ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC), a firm that is advancing immune-based therapies targeting brain diseases and other cancers. The firm is focusing resources on developing its research-stage Stem-to-T-Cell plan in collaboration with major academic researchers and contract labs. It is also continuing to assess opportunities to associate its development-stage programs.

The details

In June, ImmunoCellular obtained a Deficiency Letter suggesting that the firm is not in compliance with the shareholder’s equity condition of the NYSE American Company Guide. As mandated, the firm filed a plan with the NYSE American advising of initiatives it intends to assume, to regain compliance with the unrelenting listing criteria by December 23, 2018.

Immunotherapies are being extensively investigated as a way to advance highly specific anticancer therapies. The objective of most of these immunotherapies is to build a population of killer T cells that are planned to destroy tumor cells. ImmunoCellular Stem-to-T-Cell research plan, exhibits superiority to the current standard of care. The firm is approaching a major point in its development plans and the results from the imminent milestone should enable the firm to focus on promising treatments with the highest potential in terms of efficacy as well as market size.

In unrelated news, ImmunoCellular Therapeutics reported that Anthony Gringeri, Ph.D., the Chief Executive Officer and President, Steven Swanson, Ph.D., the Senior VP, Research, and David Fractor, who is the Chief Financial Officer, will participate in the Lytham Partners Virtual Investor Event on October 11, 2017.

ImmunoCellular Therapeutics is advancing immune-based therapies for the cure of cancer. The company is focused on developing its Stem-to-T-Cell research plan, which engineers hematopoietic stem cells to create cytotoxic T cells. Additional resources, for which the firm is seeking associates, comprise clinical-stage programs – ICT-121, ICT-140 and ICT-107. These resources are basically immunotherapies targeting solid tumors.